PPGNZ Stock Overview
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PolyPeptide Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF32.85 |
| 52 Week High | CHF34.60 |
| 52 Week Low | CHF14.11 |
| Beta | 1.04 |
| 1 Month Change | 14.06% |
| 3 Month Change | 98.13% |
| 1 Year Change | 34.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPGNZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -0.9% | -1.6% | 0.5% |
| 1Y | 34.7% | -41.3% | 6.3% |
Return vs Industry: PPGNZ exceeded the UK Life Sciences industry which returned -41.3% over the past year.
Return vs Market: PPGNZ exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| PPGNZ volatility | |
|---|---|
| PPGNZ Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PPGNZ's share price has been volatile over the past 3 months.
Volatility Over Time: PPGNZ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,273 | Juan Gonzalez | www.polypeptide.com |
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications.
PolyPeptide Group AG Fundamentals Summary
| PPGNZ fundamental statistics | |
|---|---|
| Market cap | CHF1.08b |
| Earnings (TTM) | -CHF50.86m |
| Revenue (TTM) | CHF316.77m |
3.4x
P/S Ratio-21.2x
P/E RatioIs PPGNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPGNZ income statement (TTM) | |
|---|---|
| Revenue | €320.37m |
| Cost of Revenue | €315.60m |
| Gross Profit | €4.77m |
| Other Expenses | €56.21m |
| Earnings | -€51.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 1.49% |
| Net Profit Margin | -16.06% |
| Debt/Equity Ratio | 26.6% |
How did PPGNZ perform over the long term?
See historical performance and comparison